LGALS1 and thrombocytosis disease: Galectin-1 neutralization led to a reduction in bone marrow fibrosis and cellular architecture in the MPLW515L mice (Fig. 6B), and reduced the myeloproliferative phenotype with significantly reduced thrombocytosis, polycythemia and splenomegaly (Fig. 6C – E).